The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
From recent Trading Update :-
'The Company is in the final stages of negotiation for two projects (one with an existing client and one with a potential new client), the total value of which is expected to be, in aggregate, approximately £350k. Whilst the Board anticipates that the contracts for these two projects will be signed in FY24, the majority of the revenue is now expected be recognised in the Company's next financial year ending 30 June 2025 '
We should expect to see two decent RNS releases over the next 6 weeks confirming the aforementioned contracts. This should help restore confidence and help the share price
This must be an old notice as it refers to Tabula Rasa. It would be showing on PYC website if it was current
PS did recently mention that PYC were not looking for a replacement COO in the short term
1.31 to buy at moment. Not encouraging buys with the large spread
We need to create some momentum here with more regular RNS releases. News is very slow
Most forward looking companies on AIM have Directors who are prepared to put their money where their mouth is. We need PS and others to do likewise NOW
Suzy retaining some optimism of a deal it would appear
'VAL201 remains under the Letter of Intent with TheoremRx and we noted towards the conclusion of 2023 their progression towards a merger with Nasdaq company EUDA, which marked a significant step forward in publicly revealing their progression towards financing'
Most unlikely I know that anything will happen, but I have actually taken a punt on over 100k shares today
I agree that shareholders interest in PYC should be appreciated and a reply should always be forthcoming
PYC have a small core team of employed staff. They can tap into a pool of contract labour if there is excess demand
We are now around four months into Peter Sargent's time at the helm. All the key initiatives that are currently work-in-progress - DosemeRx, Beyond Blood, Bio-statistics and also the numerous major contract relationships - result from JM's time as CEO
Under Peter's leadership we have had the move to appoint an in-house 'Head of Modelling' and a deliberate drive towards attending more conferences/events with a view to growing the reputation of the company within the industry and its pipeline. No doubt he will be working hard behind the scenes on new initiatives in order to make his mark and take the company to another level
I believe there are exciting times ahead
It seems to be a not uncommon occurrence across AIM. I have always suspected small groups of traders working in unison for small margin gains. Another scenario is someone forward selling of placing shares (is it legal ?) but see no reason for this to be a factor here. Markets often makes no sense and can be very murky
A few days ago PYC referenced a link to this recent article which suggests that 'Personalised Circadian Medicine Will Likely be a Game Changer in Oncology'
https://www.sciencedirect.com/science/article/pii/S2452310024000027
They have followed this up with a post yesterday which links to a detailed study carried out for AACR 2008 covering a Circadian Clock Model
https://www.physiomics.co.uk/wp-content/uploads/2019/04/Poster_AACR2008_no801_13April.pdf
Looks like PYC could be well positioned to take advantage of their specialist knowledge in this important area of research
The following report suggests that pressures on European cancer treatment are likely to grow significantly with 40% of specialist oncologists predicted to retire/leave over the next 5 years
https://www.rcr.ac.uk/media/hplj0uth/rcr-census_clinical-oncology-workforce-census_2022.pdf
'The need for novel oral cancer drugs, take at home and in the community, will only grow as hospital systems become more overloaded, and the numbers of specialist oncologists continues to decrease'
Must be some real opportunities here for PYC
Ant, thanks for your excellent contributions which are most interesting and welcome
PYC have been banging the drum for personalised medicine for many years. They should be well placed to take full advantage now that the industry has finally recognised its huge potential opportunities and benefits
DosemeRx have posted this which suggests they have strong growth ambitions and would be an excellent partner if PYC are able to strike a commercial deal with them
https://doseme-rx.com/news-media/article/doseme-expands-global-footprint-in-australia
On a recent IMC presentation JM mentioned that 'at the point when we mutually decide that we want to move to a commercial phase that will be quite quick because Doseme clients use the tool on a Cloud-based system and it doesn't require a complicated and lengthy roll-out'
I was a bit unsure when the company announced that it was initiating a company newsletter
However, I have been impressed by how much relevant news has been contained in the first few issues. It is a credit to the determined effort PYC are making to improve the profile of the company. Lets hope this continues in the near term with details regarding the Head of Modelling appointment, maybe an update on the G-CSF project, some important news on the Biostatistics initiative, contract announcements etc. Exciting times for those with a genuine interest
Dr Putcha was appointed as Head of Bio-statistics on 3rd October, 2023. Over six months later and we have heard nothing and he does not appear on the list of Team members on the company website
Maybe he is being kept back for the big Bio-statistics update promised sometime before 30th June ?